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Cell surface glycosphingolipids represent a large variety of antigens (1-3) and have 
been  implicated as  regulators of the  cell cycle and  of cell growth  (4)  and  also  as 
receptors for toxins and hormones (5). Plant lectins have been widely used for probing 
cell surface carbohydrates;  nevertheless,  anti-carbohydrate antibodies  have several 
advantages as compared to lectins. These include better definition of specificity, ease 
of preparing the  monovalent  form  (Fab),  and  relative lack  of toxicity. Antibodies 
directed to a pure glycolipid (6-8) or an oligosaccharide-carrier protein complex (9, 
10)  have been prepared for studies of carbohydrate distribution in tissues and cells 
(7),  as  well  as  changes  of carbohydrates  associated  with  the  cell  cycle  (11,  12), 
oncogenic transformation (13,  14), cell contact (14), and their functional modification 
(15).  However, those anti-carbohydrate antibodies  (6-10)  were polyclonal and con- 
tained a  variety of specificities. Therefore, to obtain monoclonal anti-carbohydrate 
antibodies,  we  have  utilized  the  hybridoma  technique  developed  by  Kohler  and 
Milstein (16, 17) to produce continuous cultures of hybrid cells that secrete monoclonal 
antibodies of predefined specificity. 
We describe here the isolation of two cell lines each of which produces an antibody 
specific for distinct steric portions of the carbohydrate moiety of ganglio-N-triosylcer- 
amide  (asialo  GM2) 1 (see  structure  in  Table  I).  This  carbohydrate  structure  was 
chosen because we previously demonstrated that  asialo GM2 represents a  potential 
tumor-associated cell surface marker for BALB/c 3T3 cells transformed by the Kirsten 
strain of murine sarcoma virus (18,  19). 
Materials and Methods 
Antisera.  Rabbit antiserum against mouse IgM, IgG, and IgA was purchased from Behring 
Diagnostics, American Hoechst Corp,  Somerville, N. J.  Goat antisera against purified  mouse 
IgM and IgG1  were purchased from Meloy Laboratories Inc., Springfield, Va.; anti-IgG1 was 
absorbed  with  purified  mouse  IgG3  as  previously  described  (20).  Rabbit  antisera  against 
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purified mouse IgG2a, IgG2b, IgG3, ~-light chain and )k-light chain were purchased from Miles 
Laboratories Inc., Miles Research Products, Elkhart, Ind. 
Rabbit antiserum against the purified glycolipid asialo GM2 was produced by immunizing 
a New Zealand white rabbit with an emulsion containing asialo GM2, bovine serum albumin, 
and  complete Freund's adjuvant  as previously described (18).  IgM and  IgG fractions were 
separated on a  Sepharose CL 6B column (2.5  ×  93 era) (Pharmaeia Fine Chemicals, Div. of 
Pharmacia Inc., Piscataway, N. J.) and concentrated with a collodion bag apparatus (Schleicher 
& Scheull, Inc., Keene, N. H.). 
Glycolipids and Derivatives.  Glycolipids  were obtained from the following sources and purified 
as  previously described  (21):  asialo GM2  from  guinea  pig erythrocytes;  glucosyl ceramide, 
ceramide  dihexoside, ceramide  trihexoside,  and  globoside from  human  erythrocytes; GM2 
ganglioside from the brain of a Tay-Sachs patient; and GM1 ganglioside from bovine brain. 
Lacto-N-triosylceramide was prepared from purified sialyl paragloboside of bovine erythro- 
cytes by stepwise removal of the sialic acid by mild acid hydrolysis followed by cleavage of the 
terminal galactose with fl-galactosidase. Asialo GMz was prepared by mild acid hydrolysis of 
GMa ganglioside. 
The C6 position of terminal GalNAc of asialo GM2 was oxidized to an aldehyde by galactose 
oxidase  according  to  the  method  of Suzuki  and  Suzuki  (22)  and  purified  by  thin-layer 
chromatography (TLC). 
The acetyl group in amide linkage to the GalNAc residue of asialo GM2 was removed by 
heating at 80°C for 5 h in the presence of hydrazine hydrate. The de-N-acetylated asialo GM2 
product, which was TLC purified in the solvent chloroform:methanol:water (60:35:8, vol/vol), 
had an Rf of 0.29 compared with that of 0.43 for asialo GM2. 10 #g of the free amino derivative 
gave a strong fluorescent spot when the TLC plate was sprayed with 0.03%  fluorescamine (23) 
in acetone followed by viewing under an ultraviolet light. 
The free amino asialo GM2 was re-N-acylated by dissolving 0.5-mg aliquots of the glycolipid 
in 0.5 ml MeOH plus 0.2 ml pyridine followed by adding 0.05  ml of either acetic anhydride 
(Mallinckrodt Inc., St. Louis, Mo.), propionic anhydride (Aldrich Chemical Co., Inc., Milwau- 
kee, Wis.), or butyric anhydride (Aldrich Chemical Co., Inc.). The reactions proceeded for 2 h 
at room temperature with 0.05-ml aliquots of each respective anhydride being added every 15 
min. Solvents were removed under N2 stream in the presence of excess toluene. Re-N-acetylated 
asialo GM2 comigrated with native asialo GMz on TLC in chloroform:methanol:water (60:35: 
8, vol/vol) with Rf of 0.43;  N-propionylated asialo GMz had an Rf of 0.48, and N-butyrylated 
had  an  Rf of 0.51.  The  methyl ester of GMz ganglioside was  formed by incubation  in  the 
presence of Dowex-50 (H + form)  (Bio-Rad Laboratories, Richmond, Calif.) in methanol for 3 
d at room temperature. 
Preparation of Hybrid Cell Lines.  BALB/c mice were immunized with asialo GM2 noncova- 
lently adsorbed to naked Salmonella minnesota by the procedure of Galanos et  al.  (24).  Each 
mouse received the following intravenous injections of the glycolipid-bacterial  complex in saline 
(weight ratio of glycolipid to bacteria of 1:4): 5 #g asialo GM2 on day 0,  10/tg on day 4,  15 #g 
on day 7, and 20 #g on day  12. After a  rest period of at least 2 wk the mice received a  final 
booster injection (20/xg asialo GM2) 4 d before the spleens were harvested. 
Spleen  cells  were  fused  according  to  the  method  of Kohler  and  Milstein  (16,  17)  by 
polyethylene glycol with the mutant BALB/c myeloma cell line MOPC21  NSI/1, which was 
kindly provided by C. Milstein (Molecular Research Council, Cambridge). Hybrids producing 
anti-asialo GM2 were screened, minicloned, and  cloned in  microtiter wells according to the 
method of Nowinski et al. (20).  Briefly, the screening assay utilized the finding of Holmgren 
(25) that glycolipids are adsorbed from an aqueous medium onto plastic surfaces. Asialo GM2 
(20/~g/ml in water plus sodium azide) was incubated in Microtest II wells (Falcon Labware, 
Div. of Becton,  Dickinson, & Co., Oxnard, Calif.) overnight at  37 °.  Nonspecific binding of 
antibodies to the plate was then blocked by incubation with 5% bovine serum albumin (BSA) 
in phosphate-buffered saline (PBS) for 2 h at 37°C. 
The antibody binding assay was performed in three steps:  (a)  50 #1  of culture fluid was 
incubated in each of the glycolipid-adsorbed wells for 45 min at 37°C.  Nonbound  immuno- 
globulin was then removed from  the wells by washing three times with PBS containing  1% 
BSA.  (b)  100,000  cpm of x25I-protein  A  from Staphylococcus aureus (IPA)  in 50 #1  of PBS was 
added to each well for 45 min at 37°C. The residual nonbound IPA was then removed from WILLIAM W.  YOUNG, Jr.  ET AL.  1011 
the  wells  by  washing  with  PBS.  (c)  The  immune  reactions  were  detected  by  overnight 
autoradiography of the IPA-treated Microtest plates on Kodak NS-2T film (Eastman Kodak 
Co., Rochester, N. Y.) with enhancement by x-ray intensifying screens (26). To detect mouse 
immunoglobulin classes that did not react directly with IPA, between steps (a) and (b) above, 
the wells  were incubated with  rabbit  anti-mouse immunoglobulin for 45 min at  37°C. The 
nonbound rabbit antibodies were removed by washing with PBS. 
After completion  of the  above protocol,  large  amounts  of concentrated  antibodies  from 
cloned hybridomas were prepared either by ammonium sulfate precipitation (40% saturation) 
of culture fluids or by intraperitoneal  inoculation of hybridoma cells into BALB/c mice that 
had been primed with 2,6,10,11-tetramethylpentadecane (pristane, Aldrich Chemical Co.). The 
aseites  fluid  and  sera  from such  sera  were  analyzed by electrophoresis on cellulose  acetate 
membranes (Microzomal System, Beckman Instruments Inc., Fullerton, Calif.). 
Determining Antibody Specificity.  Asialo GM2 is the major glycolipid of guinea pig erythrocyte 
membranes  (27),  and  these  cells  are readily agglutinated  by anti-asialo  GM2.  Inhibition of 
hemagglutination  was tested  using lipid  vesicles  with  mole ratio of egg lecithin:cholesterol: 
glycolipid of 1  : 1:0.1. The vesicles were diluted in microtiter plates and then preincubated with 
three hemagglutination doses of antibody solution at 4°C for 1 h. After the addition of a  2% 
suspension of guinea pig erythrocytes, the incubation was continued for 1 h at 4°C. 
Complement fixation was determined in microtiter plates using a minor modification of a 
previously  described  method  (28),  using  lipid  vesicles  with  a  mole  ratio  of egg  lecithin: 
cholesterol:glycolipid of 1  : 1:0.03. 
Antibody-complement mediated damage to glycolipid liposomes was determined according 
to the method of Six et al.  (29). 4-methyl umbelliferone phosphate (4Me-UmP)  was trapped 
inside multicompartment  liposomes prepared with a mole ratio of dimyristoyl phosphatidyl- 
choline:cholesterol:dicetyl  phosphate:glycolipid  of  1:0.75:0.1:0.04.  Release  of  the  trapped 
marker from the liposomes by appropriate antibody plus complement was detected fluoromet- 
rically  by  the  conversion  of the  fluorogenic  substrate  to  the  highly  fluorescent  4-methyl 
umbelliferone by alkaline phosphatase. Each assay tube contained alkaline phosphatase (5/~1, 
2.5 pg/ml),  25/~1 guinea pig serum as the complement source, and  the indicated  volume of 
antibody, in a total vol of 990/~1. The reaction was started by the addition of I0 #l of liposomes 
(2 mM dimyristoyl phosphatidylcholine). 
Results 
Production of Anti-Asialo  GM2 Hybridomas.  The  first  fusion  of the  NS-I/1  myeloma 
with spleen cells from three BALB/c mice immunized against asialo GM2 yielded  72 
culture  wells  from which one anti-asialo GM2-producing clone  (2D4)  was obtained. 
In immunodiffusion tests the concentrated culture fluid was shown to contain an IgM 
immunoglobulin with K-light chains. In a  second fusion using two mouse spleens, the 
supernate from 2 of 300 culture wells reacted with asialo GM2 in the initial antibody 
binding assay. Only one of these resulted in a stable clone (D 11G 10) which produced 
an  IgG3  antibody,  also  with  K-light  chains.  Interestingly,  these  results  represent 
another example of the findings ofPerlmutter et al. (30) that mouse antibodies specific 
for carbohydrates are, in addition to IgM, primarily of the IgG3 subclass. 
The levels of anti-asialo  GM2 antibodies  were initially  compared by hemaggluti- 
nation of guinea pig erythrocytes. The highest  hemagglutination  titer in the sera of 
mice immunized against asialo GM2 was  1:32-1:64. As shown in Table II the titer of 
the medium from a dense culture of the IgM-producing clone was comparable to this 
peak serum titer.  The tremendous amplification of antibody production that can be 
achieved by the hybridoma technique is indicated by the titer of the ascites fluid from 
mice bearing  the IgM-producing hybridoma which was nearly  1,000 times  stronger 
than  immune serum;  in addition  an average of ~6-8  ml ascites  fluid was obtained 
from each mouse. Animals inoculated with the IgG3-producing cells yielded only ~2- 1012  SPECIFICITY OF ANTI-GLYCOLIPID MONOCLONAL ANTIBODIES 
TABLE II 
Characteristics of Anti-Asialo GM2 Hybridomas 
Clone 2D4  Clone D11G10 
Immunoglobulin: 
Heavy chain type  /t  "/3 
Light chain type  x  K 
Hemagglutination titer:* 
Culture medium  1:32-1:64  1:4-1:8 
Ascites fluid  1:4,000-1:32,000  1:256-1:512 
Immunoglobulin concentration in 
ascites fluid, mg/ml  30-40  10-15 
* Hemagglutination of 2% guinea pig erythrocytes at 4°C. 
4 ml ascites fluid. Cellulose acetate electrophoresis indicated  that ascites fluids from 
mice bearing each hybridoma contained monoclonal gamma globulins (Fig.  1), with 
approximate immunoglobulin concentrations as indicated in Table II. 
Antibody Specificity Determined by Hemagglutination Inhibition.  The  specificity of the 
anti-asialo  GM2  hybridoma  antibodies  was  determined  using  hybridoma  culture 
medium which  had been concentrated  30-fold by ammonium sulfate precipitation. 
Several  purified  glycolipids  were  tested  initially  for  their  ability  to  inhibit  the 
agglutination  of guinea  pig erythrocytes. Asialo  GM2  completely inhibited  the  he- 
magglutination caused by each hybridoma antibody  (Table III); none of the other 
glycolipids tested caused any inhibition even at 100 #g/ml. These glycolipids included 
ceramide dihexoside  (see structures  in Table I), indicating that  the major immuno- 
determinant for both antibodies was the terminal N-acetylgalactosamine and not the 
penultimate galactose residue. GM2 ganglioside, which differs from asialo GM2 only 
by the presence of sialic  acid  attached  to C3  of the  galactose residue,  also did  not 
inhibit. To rule out the possibility that GM2 was not recognized simply because of the 
negative charge of the sialic acid carboxyl group,  the GM2  methyl ester was tested 
and found to lack inhibitory activity as well. Thus, both antibodies failed to recognize 
the  GalNAcfll--~4Gal  structure  when  a  bulky  group  was  attached  to  C3  of the 
galactose. In addition, asialo GM1 did not inhibit either antibody indicating that the 
C3 hydroxyl of the terminal GalNAc must be free. Finally, the fact that globoside did 
not  inhibit  indicated  that  both  antibodies  were  specific  for  the  GalNAcfll---~4Gal 
linkage rather than GalNAcfll-*3Gal. 
To further explore the specificity of these antibodies, several structural  analogues 
of asialo GM2 were tested  (Table I B).  Removal of the acetyl group of the terminal 
GalNAc by hydrazinolysis produced a  free amino asialo GM2 which was not recog- 
nized by either antibody (Table III). Re-acylation of the amino function with chains 
of  increasing  lengths  produced  the  following  striking  results.  The  IgM  antibody 
recognized the  re-N-acetylated, N-propionylated,  and  N-butyrylated structures,  but 
the  IgG3  was  inhibited  only  by  the  first  two  analogues  and  completely  failed  to 
recognize  the  N-butyrylated  structure.  These  results  strongly  suggested  that  the 
terminal  GalNAc  including  the  C2-moiety of asialo  GM2  represented  a  major im- 
munodeterminant for the IgG3 antibody. 
An  additional  derivative was prepared by oxidizing  the C6 hydroxyl function of 
the  terminal  GalNAc  of asialo  GM2  to  an  aldehyde  group  by  galactose  oxidase. 
Although  this  structure  inhibited  agglutination  by the  IgG3 to the same extent  as WILLIAM W.  YOUNG, Jr.  ET AL.  1013 
FEc.  1.  Electrophoretic  separation of proteins in the ascites fluid of mice bearing anti-asialo GM2- 
secreting hybridomas. Electrophoresis on cellulose acetate membranes was performed with (from 
top to bottom): a. normal mouse serum; b. ascites fluid from IgM secreting hybridoma; c. ascites 
fluid from IgG3  secreting hybridoma; d. normal mouse serum. 
native asialo GM~, it was not recognized by the IgM antibody in this assay. Therefore, 
the terminal GalNAc of asialo GM2 including C6 portion was identified as a  major 
immunodeterminant for the IgM antibody. 
A  rabbit  antiserum  specific for asialo GM~ was also tested  for its  ability to bind 
analogs of asialo GM2  (Table III). Agglutination of guinea pig erythrocytes by the 
rabbit  IgG fraction,  unlike  IgG3  antibody,  was  not  inhibited  by  asialo  GM2  C6 
aldehyde,  and  it  also  failed  to  recognize N-butyrylated asialo  GM2.  The  fact  that 
asialo  GM2  N-propionylated  caused  only  partial  inhibition  even  at  the  highest 
concentration  (100 ~g/ml)  indicates  that  the  rabbit  IgG antibodies  consisted  of a 
mixture of specificities, only some of which reacted with this derivative. Thus, it was 
difficult to define immunodominant portions ofasialo GM2 for the rabbit IgG fraction 
although the data indicate that both the C2 and C6 portion of the terminal GalNAc 
may influence  IgG antibody binding.  Similarly,  the  rabbit  IgM  fraction  was  also 
heterogeneous with respect to binding specificity, as it was only partially inhibited by 
asialo GM2 N-butyrylated and asialo GM2 C6 aldehyde. 
Specificity  Determined  by  Complement-dependent Assays.  The  specificity  of  the  two 
BALB/c monoclonal antibodies was also tested by complement fixation (Fig.  2). The 
IgM antibody failed to recognize the free amino-asialo GM~ but reacted with asialo 
GM2 and  with  the  three re-N-acylated structures  to the same degree.  There  was  a 
weak but detectable reaction of the IgM with asialo GM2 C6-aldehyde which was not 
seen in the hemagglutination inhibition assay. 1014  SPECIFICITY  OF  ANTI-GLYCOLIPID  MONOCLONAL  ANTIBODIES 
TAnLE  III 
Inhibition by Glycolipid of Guinea Pig E~ythrocyte Hemagglutination Caused by Anti-Asialo GM2 
Antibodies 
Glycolipid inhibitor 
Concentrated hybridoma su- 
pernate:  Rabbit anti-asialo GM2 
DllG10 
2D4 (IgM)  (IgG3)  IgM  IgG 
Asialo GM2 
Asialo GM2-NHe 
Asialo GM2-re-N-acetylated 
Asialo GM2-N-propionylated 
Asialo GM2-N-butyrylated 
Asialo GM2-C6 aldehyde 
Glucosylceramide 
Ceramide dihexoside 
GM2, GM2 methyl ester 
GMI, asialo GMx, globoside 
Ceramide trihexoside 
Lacto-N-t  riosylceramide 
3.1"  3.1  1.6  12.5 
> 100  > 100  ND  ND 
1.6  6.3  1.6  12.5 
1.6  3.1  3.2  12.5:]: 
0.8  >i00  6.4:t:  >100 
>100  6.2  12.55  >100 
>I00  >100  ND  ND 
ND, not determined. 
* Minimum dose of glycolipid in/tg/ml which inhibits three hemagglutination doses of antibody. Glycolip- 
ids were tested in the presence of auxiliary lipids (Materials and Methods). 
$ Inhibition even at the highest glycolipid concentrations was not complete. 
Although IgG3 Fc fragments do not appear to bind complement (31), IgG3 anti- 
asialo GM2 did fix complement in agreement with the description of another anti- 
carbohydrate IgG3 (32). The IgG3  anti-asialo GM2 culture supernate concentrated 
30-fold  had  a  complement  fixation titer  of only  1:8. Nevertheless,  this  antibody 
reacted to an equal extent with asialo GMz, the C6 aldehyde structure, and the re-N- 
acetylated and N-propionylated forms, but failed to recognize  either the free amino 
derivative or N-butyrylated asialo GMz. 
Lysis of muhicompartment glycolipid liposomes by the monoclonal antibodies plus 
complement produced specificity  patterns in agreement with the preceding assays. 
Because the complement fixing activity of the IgM antibody was so strong, it was 
possible  to analyze unconcentrated culture fluid in this assay  (Fig. 3A).  The IgM 
reacted with asialo  GM2 and the three re-N-acylated structures to the same extent. 
Reaction with liposomes  containing asialo  GMz C6-aldehyde was  very weak; only 
9.6% of the trapped marker was released  in the presence of 150/zl culture fluid. 
The concentrated IgG3 antibody in the presence  of complement produced signifi- 
cant  marker  release  from  liposomes  prepared  with  asialo  GM2,  the  C6-aldehyde 
structure  and  the re-N-acetylated and  N-propionylated derivatives  (Fig.  3B),  but 
failed to react with the asialo GM2 N-butyrylated liposomes. In addition to the data 
shown, neither the IgM nor IgG3 antibodies reacted with the following glycolipids by 
complement fixation or liposome  lysis: ceramide dihexoside, GM2 ganglioside, GM2 
methyl ester, GM1 gang!ioside, or globoside. 
Discussion 
Using the hybridoma procedure developed by Kohler and  Milstein (16, 17)  we 
have  established  continuous  cultures  of hybrid  cells  producing  two  monoclonal WILLIAM W.  YOUNG, Jr. ET AL.  1015 
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Fro.  2.  Complement fixation patterns produced by anti-asialo GM2 hybridoma antibodies of the 
IgM class (left) and IgG3 subclass (right) and various glycolipid derivatives. Abscissa,  reciprocal of 
the antibody dilution; in both cases the antibody source was culture medium from the hybridoma 
cells  which  had  been  concentrated  30-fold  by  ammonium  sulfate precipitation.  Hatched  areas 
indicate only 100% fixation. A, asialo GM2; B, asialo GM2-amine; C, asialo GM2 re-N-acetylated; 
D, asialo GM2 N-propionylated; E, asialo GM2 N-butyrylated; and F, C6 aldehyde asialo GM2. 
antibodies  specific for the glycolipid asialo GM2.  Using structural  analogs of asialo 
GM2,  we  identified  the  C6  hydroxyl-bearing group  of the  terminal  N-acetylgalac- 
tosamine residue as a  major immunodeterminant  for one of these antibodies, which 
is of the IgM class (Table III and Figs. 2 and 3 A). In contrast the other hybridoma 
antibody, which is an IgG3, recognized the C2 N-acetyl group of the terminal sugar 
as a major determinant (Table III, Figs. 2 and 3 B). It is unlikely that these differences 
seen  in  reactivity  of the  two  antibodies  might  simply be  a  result  of some general 
difference between IgM and IgG, because rabbit IgM and IgG antibodies specific for 
asialo GM2 did not display the same pattern of reactivity (Table III). Therefore, the 
simplest interpretation of our results is that the monoclonal IgM antibody is directed 
toward the C6 portion of terminal galactosamine, whereas the IgG3 antibody recog- 
nizes the C2 position, which is actually on the other side of the molecule as depicted 
in  Fig.  4.  Clearly,  both  antibodies  have some additional  recognition  of the  entire 
GalNAcfll--*4Gal structure  without  sialosyl attachment  at  the  penultimate Gal, as 
neither globoside nor GM2 ganglioside reacted with either antibody. 
Previous studies have indicated that anti-carbohydrate antibodies can possess such 
strict specificity. Natural monoclonal  IgM antibodies present  in patients with Wal- 
denstrom macroglobulinemia have been known to possess anti-carbohydrate specific- 
ity.  Some of these  antibodies,  collectively known  as  cold-reactive  anti-I  and  anti-i 
antibodies,  recognize the  following specific domains of defined carbohydrate struc- 
tures. The determinants recognized by 10 of 11  monoclonal anti-I antibodies are all 
located on various domains within the branched lacto-N-isooctaosyl structure (33, 34). 
The  determinants  recognized  by  four  out  of six  monoclonal  anti-i  antibodies  are 
located  on  various  domains  of the  lacto-N-norhexaosyl structure,  which  is  a  linear 
chain  with  two  repeating  Galfll---~4GIcNAc residues  (33-35).  These  data  provide 
additional  examples that specific domains within  the same carbohydrate chain can 
be recognized by different monoclonal antibodies. 1016  SPECIFICITY  OF ANTI-GLYCOLIPID MONOCLONAL ANTIBODIES 
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Fio.  3.  Effect  of anti-asialo GM2 hybridoma  antibodies on 4Me-UmP release from glycolipid 
liposomes. A, IgM antibody; B, IgG3 antibody. See Materials and Methods for assay details. 
Polyclonal  anti-carbohydrate  antibodies  have  also  been  shown  to  possess  strict 
specificity. For example Laine et al. (8) reported that affinity purified rabbit antibodies 
specific  for  N-glycolylhematoside  reacted  only  weakly  with  N-acetylhematoside. 
Nevertheless,  the  results  of the  present  paper  demonstrate  that  monoclonal  anti- 
carbohydrate antibodies prepared by the hybridoma technique are clearly the reagents 
of choice  in  terms  of both  the  quantity  and  specificity  of antibody  that  can  be 
produced. WILLIAM  W.  YOUNG, Jr.  ET  AL.  1017 
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Fro. 4.  Proposed  structural specificities  for BALB/c monoclona| anti-asiaIo GM2 antibodies. 
Perlmutter et  al.  (30)  have recently reported that  murine  IgG responses against 
several bacterial carbohydrate antigens are largely restricted to the rare IgG3 subclass. 
They proposed the existence of a subclass-specific regulatory mechanism in the mouse 
activated by such antigens, which may exist in other species as well. Interestingly, our 
anti-asialo GM2 IgG is also of the IgG3 subclass. The immunogen used in these studies 
was  asialo  GM2  noncovalently  adsorbed  to  an  acid-treated  mutant  of Salmonella 
minnesota (24).  Apparently such a  complex is sufficient to activate on IgG3 response. 
In conclusion, we have described the production of two anti-asialo GM2 antibodies 
which interact with distinct portions of the carbohydrate chain. Using reagents with 
such strict specificity it may be possible to probe cell surface membrane architecture 
at a  new level. For example, it is conceivable that access of exogenous reagents such 
as antibodies to one portion of a carbohydrate chain might be restricted by neighbor- 
ing  molecules,  whereas  other  regions  of the  same  chain  would  be  exposed;  such 
situations may be detectable using sets of highly specific monoclonal antibodies. 
Summary 
Two hybrid cell lines were prepared by the fusion of mouse myeloma cells with the 
spleen cells of BALB/c mice that had been immunized with the glycolipid ganglio-N- 
triosylceramide (asialo GM2). The specificity of the monoclonal antibodies produced 
by  these  hybridomas,  one  an  IgM  and  the  other  an  IgG3,  has  been  defined  by 
hemagglutination inhibition, complement fixation, and lysis of glycolipid liposomes 
by antibody and complement. 
A major determinant recognized by the IgM antibody is the nonreducing terminal 
N-acetylgalactosamine including the C6 primary hydroxyl group, but excluding the 
C2-acetamido  group  of N-acetylgalactosamine,  because  oxidation  with  galactose 
oxidase produced a structure showing only minimal cross-reaction with the IgM but 
replacement of the N-acetyl group with an N-n-butyryl group produced a  glycolipid 
that reacts with IgM antibody to the same extent as with the unmodified glycolipid. 
A major determinant recognized by the IgG3 antibody is the terminal N-acetylgalac- 
tosamine including the C2-acetamido group, but excluding the C6 primary hydroxyl 
group of N-acetylgalactosamine, because replacement of the N-acetyl group with an 
N-n-butyryl group produced a glycolipid that did not react with the IgG3 antibody; 
in striking contrast the IgG3 antibody reacted with the C6-oxidized glyeolipid as well 
as with the native glycolipid. Neither antibody reacted significantly with any other 
natural glycolipids tested including several that are structurally related to asialo GM2 
such  as  ganglioside  GM2,  ganglio-N-tetraosylceramide  (asialo  GM1),  or  ceramide 1018  SPECIFICITY OF ANTI-GLYCOLIPID MONOCLONAL ANTIBODIES 
dihexoside. These  results indicated that  in  addition to the fine structure  specificity 
described  above  both  antibodies  recognize  the  nonreducing  terminal 
GalNAc/~ 1---~4Gal structure. 
The  strict  antigenic  specificity  of  these  monoclonal  anti-glycolipid  antibodies 
indicates their great potential as specific probes for cell surface studies. 
We  thank  Dr.  C.  Milstein  (Molecular  Research  Council,  Cambridge)  for  providing the 
BALB/c myeloma cell line MOPC 21  NSI/1. 
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